A cardiology team catalogues the injectable-peptide market, compound by compound

A cardiology team catalogues the injectable-peptide market, compound by compound

Three physicians at the University of Missouri-Kansas City and Saint Luke’s Mid America Heart Institute have published a review that does something the injectable-peptide market rarely gets: a compound-by-compound account of what is claimed, what mechanism is proposed, and what could go wrong. It covers BPC-157, TB-500, CJC-1295 and ipamorelin, MK-677, melanotan-II, GHK-Cu, retatrutide and … Read more

Online-bought retatrutide, a hospital admission, and the limits of a single case

Online-bought retatrutide, a hospital admission, and the limits of a single case

A case report published on 26 August describes a man in his mid-30s with long-standing type 1 diabetes who was admitted to hospital with severe vomiting, diarrhoea, high blood sugar, ketones and acute kidney injury, shortly after self-administering a product he had bought online marketed as retatrutide. His partner took the same preparation and also … Read more

FDA warns five research-peptide sellers over GLP-1 products

FDA warns five research-peptide sellers over GLP-1 products

The FDA’s Center for Drug Evaluation and Research issued warning letters dated 24 August 2026 to five online peptide sellers — TXP Innovations LLC dba Tex Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC and Peak Performance Peptides — posted 1 September 2026. Each followed a July 2026 review of the firm’s website … Read more

Lilly files six lawsuits over black-market retatrutide sales

Lilly files six lawsuits over black-market retatrutide sales

Eli Lilly filed six lawsuits on 12 August 2026 against US entities selling black-market retatrutide, an investigational molecule in Phase 3 trials that no regulator has approved for human use. The defendants are Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide: compounding pharmacies, medical spas and online … Read more

FDA warning letter to Wholesale Peptide over Prostamax and gonadorelin

FDA warning letter to Wholesale Peptide over Prostamax and gonadorelin

On 17 June 2026 the FDA’s Center for Drug Evaluation and Research issued a warning letter to Wholesale Peptide of Brooksville, Florida, after reviewing the firm’s website in May 2026. The letter names two products, “Prostamax” and “Gonadorelin”, as unapproved new drugs under section 505(a) of the FD&C Act, quoting site copy stating that Prostamax … Read more

FDA warns five online peptide sellers over unapproved GLP-1 drugs

FDA warns five online peptide sellers over unapproved GLP-1 drugs

On 31 March 2026 the FDA’s Center for Drug Evaluation and Research issued warning letters to five websites selling injectable peptides to US buyers: Lovega LLC dba Pink Pony Peptides, Gram Peptides, Prime Sciences, Mile High Compounds and PekCura Labs. Each cites unapproved new drugs sold over the internet under sections 301(d) and 505(a) of … Read more

FDA warning letter to USA Peptide over semaglutide and tirzepatide

FDA warning letter to USA Peptide over semaglutide and tirzepatide

The FDA issued a warning letter to USApeptide.com for introducing unapproved and misbranded semaglutide and tirzepatide into interstate commerce. The agency cited inadequate directions for use and pointed to evidence that the products were intended for human applications including weight loss and diabetes management — despite research-use-only labeling. An early instance of the argument the … Read more